TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial

Bookmark and Share
Published: 3 Dec 2016
Views: 1723
Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France

Dr Mahon presents data at ASH 2016 with an update from the EURO-SKI trial of TKI cessation for myeloid leukaemia patients.

This update follows results presented at EHA 2016, which ecancer covered here.

Coverage of the press conference in which new data was presented is available here, and more detail is available through ecancer news here.

Dose reduction of TKI therapy was also discussed by Prof Mhairi Copeland, here, and these findings were discussed by Dr Mikkael Sekeres here.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.